Top 3 Genomic Sequencing Stocks To Buy On The Rebound

Big picture, Personalis should do well because there is a growing need for genomic data in immune-oncology and cancer drug development. The opportunity in liquid biopsy is especially exciting. While the company is early-stage and has faced challenges due to the COVID-19 pandemic, the pipeline of new products and a likely boost to volumes post-COVID portend good things in the second half of 2021 and beyond.

Sequencing Stock #3: Adaptive Biotechnologies (ADPT)

Adaptive Biotechnologies (ADPT) has become a leader the immune-driven medicines market, which is approaching $50 billion across research ($1 billion), diagnostics ($16 billion) and drug discovery ($31 billion). The company has a market cap of $5.7 billion.

Adaptive has developed a platform that characterizes genetic code of the body’s adaptive immune system. The platform sequences T-cell receptors (TCR) and B-cell receptors (BCR), maps receptors to antigens, pairs receptor chains, and identifies drug candidates that could be potential therapies.

The current focus is development of products to diagnose, treat and monitor diseases, including certain cancers, Lyme disease and COVID-19. One of Adaptive’s many areas of growth is ClonoSEQ, which is used to detect and monitor minimal residual disease (MRD) in bone marrow from patients with multiple myeloma, B cell acute lymphoblastic leukemia (ALL) and lymphoblastic leukemia (CLL). The number of treatable patients is expected to double in 2021.

Additionally, Adaptive has recently launched its T-Detect COVID-19 test, which can confirm past COVID infections by looking at T-cells. Next up is T-Detect Lyme, and tests for Crohn’s and Celiac are in the pipeline for 2021.

Finally, in drug development the company is working with partner Genentech for a TCR candidate that could work in multiple solid tumors. It is also working with Amgen to develop therapeutic antibodies to treat or prevent against various strains of COVID-19.

Adaptive is a high-growth company, though the pandemic has taken a toll. Revenue grew by 53% in 2019 to $85.1 million. Fourth-quarter 2021 results were solid, and full-year 2020 revenue growth was 15.6% to just under $100 million.

View single page >> |

Disclaimer: All the information in this article - is published in good faith and for general information purpose only. Hashtag Investing does not make any warranties about the completeness, ...

How did you like this article? Let us know so we can better customize your reading experience.


Leave a comment to automatically be entered into our contest to win a free Echo Show.